
Publishers page: http://dx.doi.org/10.1038/s41598-017-03054-8 <http://dx.doi.org/10.1038/s41598-017-03054-8>

Please note:
Changes made as a result of publishing processes such as copy-editing, formatting and page numbers may not be reflected in this version. For the definitive version of this publication, please refer to the published source. You are advised to consult the publisher’s version if you wish to cite this paper.

This version is being made available in accordance with publisher policies. See http://orca.cf.ac.uk/policies.html for usage policies. Copyright and moral rights for publications made available in ORCA are retained by the copyright holders.
Rare Variant Analysis of Human and Rodent Obesity Genes in Individuals with Severe Childhood Obesity

Audrey E. Hendricks1,2, Elena G. Bochukova3,4, Gaëlle Marenne1, Julia M. Keogh3, Neli Atanassova3, Rebecca Bounds1, Eleanor Wheeler1, Vanisha Mistry1, Elena Henning1, Understanding Society Scientific Group1, Antje Körner6,7, Dawn Muddyman1, Shane McCarthy1, Anke Hinney1, Johannes Hebebrand2, Robert A. Scott5, Claudia Langenberg9, Nick J. Wareham9, Praveen Surendran9, Joanna M. Howson9, Adam S. Butterworth9,10, John Danesh9,11,12, EPIC-CVD Consortium13, Børge G Nordestgaard11,12, Sune F Nielsen11,12, Shoaib Afzal11,12, Sofia Papadia3, Sofie Ashford3, Sumedha Garg3, Glenn L. Millhauser13, Rafael I. Palomino13, Alexandra Kwasniowska3, Ioanna Tachmazidou4, Stephen O’Rahilly3, Eleftheria Zeggini3, UK10K Consortium‘, Inês Barroso1,3 & I. Sadaf Farooqi3

Obesity is a genetically heterogeneous disorder. Using targeted and whole-exome sequencing, we studied 32 human and 87 rodent obesity genes in 2,548 severely obese children and 1,117 controls. We identified 52 variants contributing to obesity in 2% of cases including multiple novel variants in GNAS, which were sometimes found with accelerated growth rather than short stature as described previously. Nominally significant associations were found for rare functional variants in BBS1, BBS9, GNAS, MKKS, CLOCK and ANGPTL6. The p.S284X variant in ANGPTL6 drives the association signal (rs201622589, MAF~0.1%, odds ratio = 10.13, p-value = 0.042) and results in complete loss of secretion in cells. Further analysis including additional case-control studies and population controls (N = 260,642) did not support association of this variant with obesity (odds ratio = 2.34, p-value = 2.59 x 10^{-3}), highlighting the challenges of testing rare variant associations and the need for very large sample sizes. Further validation in cohorts with severe obesity and engineering the variants in model organisms will be needed to explore whether human variants in ANGPTL6 and other genes that lead to obesity when deleted in mice, do contribute to obesity. Such studies may yield druggable targets for weight loss therapies.

Studies focused on severe early onset obesity alone, or obesity with developmental delay and/or dysmorphic features have identified a number of genes harbouring highly penetrant causal mutations1–7. The further characterisation of rare, highly penetrant variants identified in such individuals can provide insights into the cellular and molecular mechanisms that drive obesity.

1Wellcome Trust Sanger Institute, Cambridge, UK. 2Department of Mathematical and Statistical Sciences, University of Colorado-Denver, Denver, CO, 80204, USA. 3University of Cambridge Metabolic Research Laboratories and NIHR Cambridge Biomedical Research Centre, Wellcome Trust-MRC Institute of Metabolic Science, Addenbrooke’s Hospital, Cambridge, UK. 4The Blizard Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, UK. 5Center for Pediatric Research, University Children’s Hospital Leipzig, Leipzig, Germany. 6IFB Adiposity Diseases Medical Faculty, University of Leipzig, Leipzig, Germany. 7Department of Child and Adolescent Psychiatry, Psychotherapy, and Psychosomatics, University Hospital Essen and University of Duisburg-Essen, Essen, Germany. 8MRC Epidemiology Unit, Institute of Metabolic Science, University of Cambridge School of Clinical Medicine, Cambridge, UK. 9Cardiovascular Epidemiology Unit, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK. 10The National Institute for Health Research Blood and Transplant Unit (NIHR BTRU) in Donor Health and Genomics, University of Cambridge, Cambridge, UK. 11Department of Clinical Biochemistry and The Copenhagen General Population Study, Herlev and Gentofte Hospital, Copenhagen University Hospital, Copenhagen, Denmark. 12Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark. 13Department of Chemistry & Biochemistry, University of California Santa Cruz, Santa Cruz, CA, 95064, USA. Audrey E. Hendricks and Elena G. Bochukova contributed equally to this work. *A comprehensive list of consortium members appears at the end of the paper. Correspondence and requests for materials should be addressed to I.B. (email: ib1@sanger.ac.uk) or I.S.F. (email: isf20@cam.ac.uk)
physiological mechanisms involved in energy homeostasis and human obesity, and can identify and/or validate
targets for therapeutic intervention. The aim of our study was to examine the prevalence of rare/ novel variants in
human and mouse obesity genes using high-throughput next-generation sequencing in a large cohort of individ-
uals with severe early onset obesity. Here we describe results from an analysis of 119 candidate genes sequenced
in 2,548 individuals with severe, early-onset obesity from the Severe Childhood Onset Obesity Project (SCOOP) (UK
individuals of European ancestry recruited to the Genetics of Obesity Study, GOOS; BMI standard deviation
score (SDS) > 3; onset of obesity before the age of 10 years; Methods) from the UK10K project. Our analysis
includes 737 SCOOP individuals with whole-exome sequence, and 1,811 additional SCOOP individuals, not
consented for whole-exome analysis, in whom we performed targeted sequencing. As this work was performed
as part of a consortium (UK10K project), this data was compared to 1,117 individuals with other disorders (e.g.
neurodevelopmental and rare disease) in whom exome sequencing and analysis were performed using the same
methods. For the purposes of this analysis, these individuals are designated as “controls” (Methods), although we
recognise that there are limitations with this design.

**Study Design**
SCOOP individuals likely to have congenital leptin deficiency, a treatable cause of severe obesity, were excluded
by measurement of serum leptin, and individuals with mutations in the melanocortin 4 receptor gene (MC4R)
(the most common genetic form of penetrant obesity) were excluded by prior Sanger sequencing.

We focused on six tiers of genes (Methods and Supplementary Table 1): (1) genes known to harbour vari-
ants causing human obesity alone (Obesity Alone; n = 6); (2) genes in which known variants cause human obe-
sity combined with developmental delay and/or dysmorphology (Obesity and Delay; n = 26); (3) genes in which
loss-of-function leads to obesity in mice (LoF Mice; n = 51); (4) genes in which gain-of-function leads to obe-
sity in mice (GoF Mice; n = 5); (5) genes encoding anorectic peptides and their receptors (Anorectic Molecules,
n = 7), and (6) genes in which loss-of-function is associated with other metabolic phenotypes in mice (Complex
Metabolic Effects, n = 24). Our aim was to include genes where there was sufficient evidence to indicate disorders
with Mendelian inheritance (obesity syndromes) or where complete deletion or overexpression (as opposed to
conditional knockouts) causes an obesity phenotype in mice (Methods) (i.e. genes in which inherited loss/gain of
function variants might exist). To identify variants more likely to be causally linked to obesity, we focused on rare
(MAF < 1%) and novel (not seen in the data we used for filtering) variants predicted to be functional (i.e. non-
sense variants, missense amino acid substitutions, alterations of conserved splice sites or small insertions/dele-
tions (indels) that introduced a frameshift) (Methods). We filtered our data against approximately 8,000 publicly
available sequenced samples, as well as 2,097 exomes (sequenced in parallel on the same platform as our samples)
and 3,781 whole-genome sequenced samples also from the UK10K project (Methods).

**Human Obesity Syndrome Genes.** Firstly, we sought to identify rare and novel functional variants in the
32 genes known to cause human obesity, with or without, additional developmental delay and/or dysmorphology
features (Obesity Alone, or Obesity and Delay) (Methods). We identified 11 rare potentially functional variants in
ClinVar with pathogenic/likely pathogenic status and 321 novel functional variants, which we confirmed by
Sanger sequencing (Fig. 1, Methods). Based on inheritance patterns (where available) and the functional propri-
ties of variants that have previously been characterised, variants in these genes may contribute to obesity, some-
times in a non-fully penetrant manner, in 52 (2%) individuals (Supplementary Figure 1 & Supplementary Table 2;
Fig. 2, Methods). As variants in MC4R account for approximately 5% of severe obesity in this cohort, these
findings indicate that >90% of patients within this cohort do not have their phenotype explained by variants in
known human obesity genes. Further analysis exploring the whole-exome in an agnostic manner, with appropri-
ately matched non-disease controls not available in the UK10K project, will be an aim of future investigations.

Notably, we identified thirteen clinically associated GNAS variants in fourteen SCOOP individuals (12 of these
confirmed on Sanger sequencing; 0.5%) (Supplementary Table 3). GNAS is an imprinted gene in which heterozygous loss-of-function variants are associated with obesity, short stature and skeletal abnormalities, and,
when maternally inherited, hormone resistance syndromes. As GNAS sequencing has traditionally only been
performed in individuals with classical clinical features, our findings suggest that the true prevalence in child-
hood obesity may be underappreciated. Three of the variants found in our study have been described previously
in patients with classical features (p.Y163X; p.R258W, and p.R265H). We identified a novel nonsense variant
(p.Y169X) predicted to remove the entire Ras-like GTPase domain and several missense variants predicted to
affect downstream signalling by affecting the interaction with G-protein coupled receptors (GPCRs), G-protein
β- and γ-subunits, or downstream adenylyl cyclase when mapped onto the protein structure of GNAS (Fig. 3). We
confirmed maternal transmission of variants in three out of the five families where parental samples were avail-
able for genotyping. Although four GNAS variant carriers exhibited endocrinopathies and nine had developmental
delay as anticipated, unexpectedly four individuals had accelerated linear growth in childhood (height SDS > 2)
rather than short stature (defined as height SDS < 2.0) (Supplementary Table 3). Further molecular and physiolog-
ical studies will be needed to investigate potential genotype-phenotype correlations. As studies in rodents have
shown that Gnas is imprinted in the paraventricular nucleus of the hypothalamus, the location of the majority of
neurons expressing the G-protein coupled receptor MC4R, it is plausible to hypothesize that some GNAS variants
may contribute to obesity and accelerated linear growth by reducing melanocortin signalling.

Next we formally tested for enrichment of rare, or novel, functional variants in case-control analysis (Methods).
Although no gene attained experiment-wide threshold of p-value < 2 × 10−4 (Methods and Supplementary Tables 4–9), four genes (BBS1, BBS9, GNAS, and MKKS) known to cause obesity and develop-
mental delay and/or dysmorphology (Obesity and Delay) had nominally significant burden test p-values (p-value < 0.05) and a higher burden of variants in cases than controls (Table 1).
Mouse Obesity Genes. We found a higher burden of rare variants in cases than controls for two genes known to cause obesity when disrupted in mice - ANGPTL6 and CLOCK (Table 1). Testing the functional consequences of CLOCK variants in cells is not straightforward as the molecular mechanisms that lead to obesity are not fully understood. As such, we focused on verifying the accuracy of the computationally predicted function of all twelve rare ANGPTL6 variants (Methods, Fig. 4, Supplementary Table 10). All variants found in cases (but not the one variant found exclusively in controls, V143L) were predicted to affect the fibrinogen-like domain of the protein (Fig. 4a). ANGPTL6 is predominantly expressed in the liver but is also expressed in white adipose tissue and kidney. To evaluate the effect of these variants, HEK293 cells were transiently transfected with constructs encoding wild type and variant forms of ANGPTL6. Whereas wild-type ANGPTL6 was readily detected in the medium, several mutants reduced, and the S286X mutant abolished, secretion of ANGPTL6 (Fig. 4b). Incorporation of this functional information did not qualitatively change the results of the ANGPTL6 gene-based test (Supplementary Table 10). However, limiting the analysis to the single variant that completely abolished protein secretion (p.S286X, rs201622589) led to an adjusted OR = 10.13 and p-value = 0.028 (Fisher’s p-value = 0.041) suggesting that the association signal at this gene is primarily driven by this variant (Supplementary Table 10). To increase power, and given that there were no additional cases of European descent from our obesity cohort, we analysed existing exome-chip data from an additional 253,587 unrelated European, non-Finnish population controls (Methods, Supplementary Table 11). In an updated analysis with the 2,548 cases and 253,587 controls, we observed an odds ratio (OR) = 2.90 and a Fisher’s p-value = 0.0022, which did not reach experiment or exome-wide significance. Further analysis of 1,436 non-overlapping obesity cases and 1,954 non-overlapping controls from two studies did not lend additional support, and when combined with the original data, yielded an overall OR = 2.34 and chi-squared p-value = 0.0060 (total 3,984 cases vs 256,658 controls, Supplementary Table 11). These findings highlight the difficulty in studying very rare variants in complex diseases, and potentially the effect of winner’s curse, reinforcing the need for extremely large sample sizes. As ANGPTL6 is a liver-derived circulating peptide, and thus could potentially be manipulated for therapeutic purposes, further genetic studies in larger cohorts and experimental studies in mice and humans are necessary to explore its role in obesity and potential utility as an anti-obesity drug target.

Power and Gene Set Analysis. Assuming an experiment-wide significance level of $2 \times 10^{-4}$ and that 30% of rare (MAF < 1%) variants within a given gene are causal we have very limited power (~20%) to detect an association to a gene region using our sample of 2,548 cases and 1,117 controls (Supplementary Figure 2, Online Methods, Supplementary Note 4). As there is evidence that looking across group of genes with stronger priors may increase power, we tested for association of rare or novel functional variants within each of the six gene sets.
candidate gene sets. We further filtered variants with respect to their likelihood of being deleterious and performed six nested tests for each gene set (Methods). Although none of the analyses of tiered gene sets reached experiment-wide significance (Supplementary Table 13, Fig. 5), we see an increase in OR as we focus on rarer variants with more evidence of predicted deleterious effect within the Obesity Alone gene set. This suggests that focusing on extremely rare variants with strong evidence of being deleterious may be a good strategy for diseases with a complex genetic architecture, which likely includes rare, highly penetrant alleles. Our power analyses also suggests that restricting the MAF threshold to be near the very rare allele frequency of that expected for the causal variants, rather than a more lenient MAF threshold of 1%, increases power (Supplementary Figure 3). Finally, there are nominally significant signals (p-value < 0.05) within the LoF Mice candidate gene set for the novel, functional variant tests suggesting that within this rather large gene set (n = 51) there may be additional genes associated with human early onset obesity (Fig. 5).

Discussion
In summary, analysis of sequence data in 119 genes across 2,548 severely obese children and 1,117 other disease controls from the UK10K project identified variants in known obesity genes, contributing to obesity in 2% of children within this cohort, in whom mutations in MC4R and leptin had been excluded. It also highlighted that GNAS mutations may be more prevalent in human obesity than previously thought, and that the spectrum of phenotypic consequences may be broader and more heterogeneous than previously described (6). Additional detailed genotype-phenotype studies will be required to further elucidate the molecular underpinnings of the physiological consequences of these variants.

Taking the information generated in this study together with the published literature, we suggest that molecular genetic investigations, including testing known obesity genes, or agnostic exome-wide or genome-wide approaches (as these become more established at the point of care), should become part of the assessment for a child presenting with severe obesity (BMI SDS > 3) in the absence of other syndromic features. Genetic studies can allow the identification of congenital leptin deficiency which is entirely treatable with recombinant leptin therapy18. Also, early reports suggest that patients with mutations that disrupt POMC signalling may be effectively
treated with Setmelanotide (a MC4R agonist)\(^{19}\). Finally, our data suggest that focusing on very rare, deleterious variants may increase power to find genetic association. Further detailed investigation of genes that lead to obesity when deleted in mice may identify new pathophysiological mechanisms involved in human obesity that can be targeted for drug discovery.

**Methods**

**Sample Sets.** All studies were approved by the Cambridge Local Research Ethics Committee and all participants and their parents gave written informed consent. All methods were performed in accordance with the relevant laboratory/clinical guidelines and regulations.

The SCOOP cohort\(^{3}\) was studied as part of the UK10K consortium\(^{4}\). Data was compared to subsets within the neurodevelopmental and rare disease groups that were consented for use as controls. Details and further
information about the UK10K project can be found at [http://www.uk10k.org/](http://www.uk10k.org/) and in the UK10K consortium paper from 2015.

We gathered the genotypes for the variant S284X (rs201622589) in 202,981 unrelated population controls with European non-Finnish ancestry from existing cohorts ([UKHLS](#), Fenland, EPIC Norfolk, CCHS, CGPS, CIHDS, EPIC-CVD, UK Biobank and ExAC) and in two additional studies of obese children and healthy or thin controls including one from the Leipzig Childhood Obesity Cohort. (Supplementary Note 1)

### Sequencing, Variant Calling, and Quality Control.

Targeted Sequencing (TS) and Whole Exome Sequencing (WES) was performed as described elsewhere (refs 33 and 4 respectively). All UK10K WES samples from all arms of the exome study available at the time of the variant calling and SCOOP TS samples (N = 5,233 and 2,819 respectively) were called together on the non-redundant targets +/− 100 bp using multi-sample calling. Using SAMtools, a BCF file was created and the site genotype likelihoods were calculated. Variants (SNPs and Indels) were called using BCFTools. Indels were left-aligned using `vcf norm` from the htslib package. Variants were filtered for sequencing and genotype quality at the site and genotype level using `vcf-annotate`.

### Variant Annotation.

All variant annotation was applied using the GRCh37 human reference. Variants were annotated with rsIDs from dbSNP 137, and allele frequencies from the final 1000Genomes Phase 1 integrated (v3) callset, the NHLBI Exome Sequencing Project (ESP) v2, and the UK10K WGS sample set. The Ensembl Variant Effect Predictor ([http://www.ensembl.org/info/docs/variation/vep/index.html](http://www.ensembl.org/info/docs/variation/vep/index.html)) v2.8 with Ensembl 66 was used to add variant consequence annotations including the predicted deleteriousness of each missense variant as predicted by SIFT, PolyPhen, and Condel. For the 32 known human obesity genes, only the variant consequences on the most clinically relevant transcript were considered for further analysis. For the other 87 candidate obesity genes, the most severe consequence on any transcript was retained for each variant (Supplementary Table 1). Using Sequence Ontology terms, variant consequences were defined as functional (i.e. essential splice site, stop gained, stop lost, complex indel, frameshift coding, non synonymous coding, within mature miRNA, partial codon).

To identify rare variants, we used the thirteen UK10K WES sample sets that were not obese sample sets and were not included as controls in this study (Supplementary Note 1). These sample sets were processed in parallel with our cases and controls and thus provide a similar sequencing coverage and depth across the called regions. We removed variants that had a MAF > 1% across all or a MAF > 10% in any of the thirteen sample sets. We then removed variants with a MAF > 1% in any of seven additional sample sets: 1. UK10K WGS sample set, 2–3. European and African American NHLBI ESP v2 sample sets, and 4–7, the four continent sample sets (AFR, AMR, ASN, EUR) from 1000 Genomes Phase 1 integrated v3 call set. Novel variants were identified as sites not seen in any of the internal or external datasets used for MAF annotation, i.e. novel at the time of this study.

### Sample quality control.

Samples were identified as contaminated using a combination of two methods: VerifyBamID v1.0 and “fraction skewed hets”. For the TS samples, the FREEMIX value was estimated using 11,250 high quality, autosomal, biallelic SNPs with an alternate AF ≥ 0.1, and a call rate ≥ 0.5 in both the TS sample set and the 1000 Genomes Project Phase 1 v3. Of the 2,819 TS SCOOP samples, the 784 WES SCOOP samples, and the 1427 WES samples used as controls 37, one, and nine were excluded due to contamination.

### Table 1. Summary of case-control results. Summary of case-control results in genes with nominally significant (p-value < 0.05, bold) burden of Rare (top) or Novel (bottom) functional variants in SCOOP cases (N = 1,811 with targeted sequence and N = 737 with whole-exome sequence), compared to 1,117 controls with whole-exome sequence data from the UK10K project. The number of variants (# variants) per gene are shown, as well as the number of alleles in cases and controls, odds ratios (OR) and p-values from SKAT-O (p-value SKATO) and from burden tests (p-value BURDEN). For variants not detected in controls an adjusted odds ratio (Adjusted OR) was calculated by adding 0.5 to the number of alleles in each cell of the two-by-two table.
respectively. Sixteen non-contaminated TS samples were excluded based on a mean sample read-depth 3 SD below the average for all samples (i.e. mean sample read-depth < 12.09). Genotype concordance for 436 WES SCOOP samples and 1,035 TS SCOOP samples for which we had both sequence and GWAS data was also calculated. Four WES samples and six TS samples with a concordance rate below 90% were identified and excluded. A set of highly polymorphic markers (MAF > 0.3) was genotyped and compared to the sequencing calls from each sample. Non-concordant WES samples were removed prior to variant calling and are not included in the original sequencing numbers. Eighty-one TS samples with low concordance were removed after variant calling. Three TS samples were removed due to having an extremely high genotype missing rate of > 50%.

To identify non-European samples, we calculated principal components (PCs) from the 1000Genomes Phase I integrated call set using either EIGENSTRAT v4.2 or LASER 2.0 for the WES and TS samples respectively (Supplementary Note 3). Of the 2,676 TS samples, 837 were classified as non-European due to genetic ancestry and three were excluded due to a reported non-European ancestry resulting in 1,836 good quality TS samples of European ancestry. Of the 779 WES SCOOP samples, 37 samples were classified as non-European due to genetic ancestry resulting in 742 good quality WES SCOOP samples of European ancestry. Of the 1,418 control samples, 146 were identified as being non-European leaving 1,272 high quality WES controls.

Known and cryptic relatedness was identified by estimating pairwise identity by descent using PLINK v1.07. Genetic relationships within the WES sample set is described in detail elsewhere. We removed individuals sequentially by: (1) largest number of relationships, (2) diseased controls, non-diseased controls, cases, (3) lower mean depth of sequencing. Five SCOOP cases and 155 controls were removed resulting in 737 SCOOP WES cases and 1,117 WES controls all of high quality, unrelated, and European ancestry. A similar process was used to identify genetic relationships within the TS sample set and between the TS and WES sample sets (Supplementary Note 3). This resulted in 25 additional exclusions (18 TS cases related to WES cases and seven related within the TS sample set) for a total of 1,811 high quality, unrelated, TS samples of European ancestry.

Figure 4. Functional characterisation of ANGPTL6 variants location and functional effect (A) Human ANGPTL6 protein and location of the genetic variants. Schematic of the human ANGPTL6 protein with the three recognisable domains: signal peptide (SP) in green, coiled-coil domain (CCD) in purple, and fibrinogen-like domain (FLD) in yellow. As all genetic variants identified are located predominantly in the FLD, the partial tertiary structure of the C-terminal protein portion (amino acids 135–470), based on previously solved fibrinogen structure (1lwu) is presented. The single variant seen in controls only is shown in blue, variants identified in cases are in purple, the S284X variant is starred. (B) Functional characterisation of ANGPTL6 variants. Cells were transiently transfected with constructs encoding wild-type (WT) or mutant ANGPTL6; levels of protein secretion into the media were measured by ELISA; means+/− standard deviation (SD) for experiments performed in triplicate are shown (results were confirmed by Western blotting; data not shown). Statistical significance was measured using unpaired T-test with Welch’s correction using the GraphPad Prism software. *p < 0.05; **p < 0.001.
Candidate Gene Sets. We performed database searches using keywords 'obesity', 'growth', 'size', 'adipose tissue', (details below) and manually curated the results to arrive at a set of six tiers of candidate gene with definite or likely links to obesity. The Online Mendelian Inheritance of Man (OMIM database, http://www.omim.org/) accessed in February, 2013 was used to identify 32 genes (Supplementary Table 1) which directly lead to human obesity. These were further categorised into two groups based on consistent clinical features: genes characterised by "Obesity alone" (Obesity Alone; n = 6), and "Obesity and developmental delay and/or dysmorphology" (Obesity and Delay; n = 26). Any putative list of candidate genes has limitations and other genes that contribute to energy homeostasis/obesity in animal models deserve interrogation in the future.

Genes that cause obesity when disrupted in rodents were identified using the Mouse Genome Informatics Database (MGI, http://www.informatics.jax.org/) and the Rat Genome Database (RGD, http://rgd.mcw.edu) both accessed in February 2013, as well as published research (www.ncbi.nlm.gov/Pubmed). Eighty-seven genes were associated with a growth/size phenotype when perturbed in rodent animal models. We evaluated the strength of evidence for a role of each gene in obesity phenotype and divided them into four further categories, specifically: Loss of function associated with obesity in mice (LoFMice; n = 51); gain of function associated with obesity in mice (GoFMice, n = 5); anorectic peptides and receptors (Anorectic Molecules, n = 7); loss of function associated with other metabolic phenotypes in mice (Complex Metabolic Effects, n = 24) (Supplementary Table 1).

Sequence validation of rare functional variants. Novel, functional variants in all 119 candidate genes were taken forward for validation by conventional Sanger sequencing (90% validation rate). Briefly, customized PCR primers were designed +/− 250 bp surrounding the variant; and sequencing was performed using BigDye Terminator v3 kit (Applied BioSystems) and analysed by capillary electrophoresis on an ABI3730 DNA Analyzer platform (Applied Biosystems), according to the manufacturer’s instructions. Familial segregation analysis of variants was performed where family samples were available.

Identification of clinically-associated variants in known human obesity genes. The strategy for identification of clinically-associated variants in known human obesity genes is outlined in Fig. 1. Briefly, novel and rare variants in the known human obesity genes were filtered using the ClinVar database (http://www.ncbi.nlm.nih.gov/clinvar/). We retained novel variants and those with a ClinVar status of Pathogenic/Likely pathogenic (N = 332).

Structural Analysis of GNAS Variants. For structural analysis of the genetic variants and prediction of their impact on protein function, we modelled their location in relation to previously solved protein crystal structures of GNAS in complex with either G-protein coupled receptor (ADRB2) or downstream effector (adenylyl cyclase). Specifically, the first model represented in Fig. 3a is based on crystal structure of the active state ternary protein complex of GPCR beta-2-adrenergic receptor (ADRB2), and the nucleotide-free Gs heterotrimer, composed of Gs-α(GNAS), Gs-β, and Gs-γ subunits (ref. 20, PDB number: 3SN6, www.rcsb.org). The second model, represented in Fig. 3b, is based on complex of GNAS with the catalytic domains of mammalian adenylyl cyclase (ref. 21, PDB...
number: 1AZS, [www.rcsb.org](http://www.rcsb.org). The structural representations using ribbon-depicted models were generated using the Open-Source PyMOL Molecular Graphics System, Version 1.7.x Schrödinger, LLC ([http://pymol.org](http://pymol.org)).

**Association Analyses.** We implemented the optimal Sequence Kernel Association Test SKAT-O[^11,^33] with the SKAT R package v1.2.2[^41] using options method = "optimal.adj" for SKAT-O and r.corr = 1 for burden. For each gene and candidate gene set, we performed two primary tests using the burden test: 1. rare functional (Rare Func) or (2) novel functional (Novel Func). We performed secondary tests restricting either to variants that were predicted to be deleterious by at least one of the three algorithms (i.e. SIFT, PolyPhen, and Condel) (1 + del) or to variants that were predicted to be deleterious by all three algorithms (all del). For SIFT and Condel, variants were classified as deleterious if they were labelled as “deleterious”. For PolyPhen, variants were classified as deleterious if they were labelled as “probably damaging” or “damaging”. Our conservative Bonferroni adjusted significance level of the primary analyses for 119 genes and 6 gene sets was 0.05/(2 × 125) = 2.0E-4. Once considering our additional ten secondary tests, our Bonferroni adjusted significance level was 0.05/(12 × 125) = 3.3E-5. We repeated all primary and secondary tests using SKAT-O (Table 1; Supplementary Table 4–9, 13).

**Functional studies of variants in ANGPTL6.** To predict the impact of variants on the ANGPTL6 protein, we modelled their location using the crystal structure of a related protein fibroglin in a complex with a peptide Gly-His-Pro-amide (described in Yang et al.[^30], PDB number: ILWU, [www.rcsb.org](http://www.rcsb.org)). The structural representations using ribbon-depicted models were generated using the Open-Source PyMOL Molecular Graphics System, Version 1.7.x Schrödinger, LLC ([http://pymol.org](http://pymol.org)). N-terminal triple Flag tag was added to human ANGPTL6 cDNA cloned into a pEZZ-M14 mammalian expression vector (Capital Bioscience). Mutations were introduced into this construct using QuikChange (Agilent technologies), and confirmed by Sanger sequencing. ANGPTL6 protein expression was studied by transient transfection in L6 (MAF = 0.0091) cells. Media was collected 48 h – post transfection, the cell medium was centrifuged for 5 min (5,000 g at 4 °C) and the supernatants were collected. Cells were harvested prior to centrifugation for 15 min (15,000 g at 4 °C). Aliquots from the medium and cells were subjected to SDS-PAGE and immunoblot analysis. Primary antibodies (monoclonal Flag M2 antibody (Sigma) and a polyclonal antibody to Calnexin (Cell signalling)) were used at 1:1000, and secondary Horseradish peroxidase–conjugated anti-mouse or anti-rabbit IgG (Dako) antibody at 1:2000 dilution. After staining with ECL West Dura Substrate kit (Thermo Scientific), visualisation was performed on Chemidoc Digital Image (Bio-Rad) (Supplementary Information). The relative protein secretion of ANGPTL6 for each variant was standardized to wild-type protein secretion. Experiments were performed in triplicate and analysed using an unpaired T-test with Welch’s correction.

**ANGPTL6 statistical follow-up analyses.** We ran gene-based analyses using SKAT-O as described above on two subsets of ANGPTL6 variants (Supplementary Table 10): (1) the one variant that resulted in a complete loss of protein secretion (S284X; rs201622589), and (2) excluding S284X. For (1), we also used a Fisher’s Exact Test. We repeated the Fisher’s Exact Test of the S284X variant including additional population controls with pre-existing genotypes and the haplotype dataset within the SKAT R-package[^5]. We performed power calculations using 500 simulations on a random 2Kb sub region. The effect sizes of the causal variants are equal to log_{10} (MAF) with a maximum effect size of 1.6 (MAF ≤ 0.0001) and all have the same direction of effect. We limited the MAF threshold for causal variants to ≤ 0.01, 0.001, 0.0005 and varied the percentage of causal variants in the region to be between 10–90%. (More details in Supplementary Note 4).

**References**

24. Kamstrup, P. R., Tybjerg-Hansen, A., Steffensen, R. & Nordestgaard, B. G. Genetically elevated lipoprotein(a) and increased risk of myocardial infarction. *JAMA* 301, 2331–9 (2009).
50. Online Mendelian Inheritance in Man, OMIM®. McKusick-Nathans Institute of Genetic Medicine, Johns Hopkins University (Baltimore, MD), (http://omim.org/) (February, 2013).
52. The Rat Genome Browser (RGD), Rat Genome Database Web Site. *Medical College of Wisconsin, Milwaukee, Wisconsin* http://rgd.mcw.edu/ (February, 2013).

**Acknowledgements**

We are indebted to the patients and their families for their participation and to the physicians involved in the Genetics of Obesity Study (GOOS). This work was supported by the Wellcome Trust (ISF, IB) (098497/Z/12/Z, WT098051), Medical Research Council (ISF, SO/R), Bernard Wolfe Health Neuroscience Endowment (ISF), European Research Council (ISF) and NIH grant DK04265 (GLM), the European Community’s Seventh Framework Programme (FP7/2007–2013) project Beta-JUDO n°279153 (ISF, AK). This study comprises one arm of the UK10K Consortium (WT091310). The UK Household Longitudinal Study is led by the Institute for Social and Economic Research at the University of Essex and funded by the Economic and Social Research Council. The survey was conducted by NatCen and the genome-wide scan data were analysed and deposited by the Wellcome Trust
Sanger Institute. Information on how to access the data can be found on the Understanding Society website https://www.understandingsociety.ac.uk/. AH and JH were funded by the German Ministry for Education and Research (National Genome Research Net-Plus 01G50820), the German Research Foundation (DFG; HI865/2-1), the European Community’s Seventh Framework Programme (FP7/2007-2013) under grant agreements n°245009 and n°262055. We thank participants and staff of the Copenhagen City Heart Study, Copenhagen Ischemic Heart Disease Study, and the Copenhagen General Population Study for their important contributions (CCHS, CGPS, CIHDS). CHD case ascertainment and validation, genotyping, and clinical chemistry assays in EPIC-CVD were supported by grants awarded to the University of Cambridge from the EU Framework Programme 7 (HEALTH-F2-2012-279233), the UK Medical Research Council (G0800270) and British Heart Foundation (SP09/002), the European Research Council (268834), the UK National Institute for Health Research Cambridge Biomedical Research Centre, Merck and Pfizer. We thank all EPIC participants and staff for their contribution to the study, the laboratory teams at the Medical Research Council Epidemiology Unit for sample management and Cambridge Genomic Services for genotyping, Sarah Spackman for data management, and the team at the EPIC-CVD Coordinating Centre for study coordination and administration (EPIC-CVD). JD is supported by a British Heart Foundation Professorship, NIHR Senior Investigator, European Research Council Senior Investigator. Leipzig LIFE Child as part of the Leipzig Childhood Obesity cohort was funded by the European Union, by the European Regional Development Fund (ERFD) by means of the Free State of Saxony within the framework of the excellence initiative. This research has been conducted using the UK Biobank Resource.

**Author Contributions**


**Additional Information**

**Supplementary information** accompanies this paper at doi:10.1038/s41598-017-03054-8

**Competing Interests:** The authors declare that they have no competing interests.

**Publisher’s note:** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2017
Consortia
Understanding Society Scientific Group

Michaela Benzeval14, Jonathan Burton14, Nicholas Buck14, Annette Jäckle14, Meena Kumari14,
Heather Laurie14, Peter Lynn14, Stephen Pudney14, Birgitta Rabe14 & Dieter Wolke15
14Institute for Social and Economic Research, University of Essex, Colchester, UK. 15University of Warwick, Warwick, UK.

UK10K Consortium

Saeed Al Turki16, Carl A. Anderson1, Richard Anney17, Dinu Antony18, Maria Soler Artigas19,
Muhammad Ayub20, Senduran Bala1, Jeffrey C. Barrett3, Phil Beales18, Jamie Bentham21,
Shoumo Bhattacharya22, Ewan Birney22, Douglas Blackwood23, Martin Bobrow24, Patrick
F. Bolton25,26,27, Chris Bousted28, Gerome Breen26,27, Mattia Calissano29, Keren Carss1,
Ruth Charlton30, Krishna Chatterjee3, Lu Chen31, Antonio Ciampi32, Sebahattin Cirak29,33,
Peter Clapham1, Gail Clement56, Guy Coates3, Massimiliano Cocca25,26, David A. Collier27,27,
Catherine Cosgrove25, Tony Cox2, Nick Craddock28, Lucy Crooks39, Sarah Curran25,40,41,
David Curtis42, Allan Daly1, Petr Danecek1, Ian N. M. Day43, Aaron Day-Williams44, Anna
Dominiczak45, Thomas Down46, Yuanping Du47, Ian Dunham22, Richard Durbin1, Sarah
Edkins1, Rosemary Ekong48, Peter Ellis1, David M. Evans49,50, David R. Fitzpatrick51, Paul
Flick22, James Floyd52, A. Rehan Foley29, Christopher S. Franklin1, Marta Futenma53,
Louise Gallagher17, Tom R. Gaunt54, Matthias Geihs1, Daniel Geschwind55, Celia M. T.
Greenwood12,55,56,57, Heather Griffin58, Detelina Grozева4, Xiaoxiao Guo47,59, Xueqin
Guo60, Hugh Gurling60, Deborah Hart24, Peter Holmans24, Bryan Howie16, Jie Huang1, Liren
Huang61, Tim Hubbard62,63, Steve E. Humphries53, Matthew E. Hurles64, Pirro Hysi165, Valentina
Iotchkova42,42, David K. Jackson1, Yadla Jamshidi32, Chris Joyce1, Konrad J. Karczewski63,64,
Jane Kaye48, Thomas Keane1, John P. Kemp49,50, Karen Kennedy1,65, Alastair Kent56, Farrah
Khawaja67, Margriet van Kogelenberg38, Anja Kolb-Kokocinski3, Genievne Lachance34,
Cordelia Langford6, Irene Lee69, Monkol Lek63, Rui Li35,56,70, Yingrui Li67,
Jieqin Liang67, Hong Lin67, Ryan Liu71, Jouko Lönqvist72, Luis R. Lopes73,74, Margarida
Lopes25,75,76, Daniel G. MacArthur43,44, Massimo Mangino34,77, Jonathan Marchini75,78,
John Maslen1, Iain Mathieson73, Peter Mcguinness79, Andrew M. McIntosh79, Andrew G.
McKeanie23,80, Andrew McQuillin60, Yasin Memari2, Sarah Metrustry1, Nicola Migone81,
Josine L. Min69, Hannah M. Mitchison19, Alireza Moayeri36,52, Andrew Morris83, James
Morris3, Francesco Muntoni29, Kate Northstone49, Michael C. O’Donovan34, Alexandros
Onoufriadis46, Karim Ouakacha84, Michael J. Owen38, Aarno Palotie85,86, Kalliope
Panoutsopoulou1, Victoria Parker3, Jeremy R. Parr87, Lavinia Paternoster49, Tiina Paunio72,88,
Felicity Payne1, Stewart J. Payne89, John R. B. Perry8,89, Olli Pietiläinen72,85, Vincent Plagnol90,
Rebecca C. Pollitt90, David J. Porteous92, Sue Povey8, Michael A. Quail1, Lydia Quaye84, F.
Lucy Raymond84, Karola Rehnström1, J. Brent Richards32,34,55,56,70, Cheryl K. Ridout91, Susan
Ring92, Graham R. S. Ritchie22, Nicola Roberts24, Rachel L. Robinson20, David B. Savage24,
Peter Scambler18, Stephan Schifflers1, Miriam Schmits18,95, Nadia Schoenmakers2, Richard
H. Scott18,96, Robert K. Semple1, Eva Serra1, Sally I. Sharp60, Adam Shaw79, Hashem A.
Shihab6, Jo-Syoun Shin1,49, David Skuse62, Kerrin S. Small34, Carol SME1, Blair H. Smith98,
George Davey Smith69, Nicole Soranzo1,31, Lorraine Southam175, Olivia Spasic-Bovsic4,
Timothy D. Spector39, David St Clair99, Beate St Pourcain100,101,101, Jim Stalker1, Elizabeth
Stevens1, Jianping Sun33,55, Gabriela Surdulescu34, Jaana Suvisaari72, Petros Syrris73, Rohan
Taylor67, Jing Tian17, Nicholas J. Timpson19, Martin D. Tobin19,102, Ana M. Valdes34, Anthony
M. Vandersteen103, Parthiban Vijayarangakannan1, Peter M. Visscher50,104, Louise V. Wain19,
Kirsten Ward34, Tamieka Whyte29, Hywel J. Williams38,108, Kathleen A. Williamson51, Crispian
Wilson24, Scott G. Wilson24,109,110, Kim Wong1, ChangJiang Xu32,55, Jian Yang50,106, Feng
Zhang34, Pingbo Zhang67 & Hou-Feng Zheng55,56,70

1The Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton CB10 1HL, Cambridge, UK.
16Department of Pathology, King Abdulaziz Medical City, P.O. Box 22490, Riyadh 11426, Saudi Arabia. 17Department of Psychiatry, Trinity Centre for Health Sciences, St James Hospital, James’s Street, Dublin 8, Ireland. 18Genetics and Genomic Medicine and Birth Defects Research Centre, UCL Institute of Child Health, London WC1N 1EH, UK.
19Departments of Health Sciences and Genetics, University of Leicester, Leicester LE1 7RH, UK. 20Division of Developmental Disabilities, Department of Psychiatry, Queen’s University, Kingston, Ontario N6G 0A7, Canada.
21Department of Cardiovascular Medicine and Wellcome Trust Centre for Human Genetics, Roosevelt Drive, Oxford
OX3 7BN, UK. European Molecular Biology Laboratory, European Bioinformatics Institute, Wellcome Trust Genome Campus, Hinxton, Cambridge CB10 1SD, UK. 21Division of Psychiatry, The University of Edinburgh, Royal Edinburgh Hospital, Edinburgh EH10 5HF, UK. 3Academic Laboratory of Medical Genetics, Box 238, L6 Addenbrooke’s Treatment Centre, Addenbrooke’s Hospital, Cambridge CB2 0QQ, UK. 22Department of Child Psychiatry, Institute of Psychiatry, Psychology and Neuroscience, King’s College London, 16 De Crespigny Park, London SE5 8AF, UK. 23NIHR BRC for Mental Health, Institute of Psychiatry, Psychology and Neuroscience and SLAM NHS Trust, King’s College London, London, UK. 16 De Crespigny Park, London SE5 8AF, UK. 24MRC Social, Genetic and Developmental Psychiatry Centre, Institute of Psychiatry, Psychology and Neuroscience, King’s College London, Denmark Hill, London SE5 8AF, UK. 25North East Thames Regional Genetics Service, Great Ormond Street Hospital NHS Foundation Trust, London WC1N 3JH, UK. 26Dubowitz Neuromuscular Centre, UCL Institute of Child Health & Great Ormond Street Hospital, London WC1N 1EH, UK. 27Leeds Genetics Laboratory, St James University Hospital, Beckett Street, Leeds LS9 7TF, UK. 28Department of Haematology, University of Cambridge, Long Road, Cambridge CB2 0PT, UK. 29Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Montreal, Quebec H3A 1A2, Canada. 30Institut für Humangeographie, Uniklinik Köln, Kerpener Straße 34, 50931 Köln, Germany. 31The Department of Twin Research & Genetic Epidemiology, King’s College London, St Thomas’ Campus, Lambeth Palace Road, London SE1 7EH, UK. 32Medical Genetics, Institute for Maternal and Child Health IRCCS “Burlo Garofolo”, 34100 Trieste, Italy. 33Department of Medical, Surgical and Health Sciences, University of Trieste, 34100 Trieste, Italy. 34Lilly Research Laboratories, Eli Lilly & Co. Ltd., E6l Wood Manor, Sunninghill Road, Windlesham GU20 6PH, UK. 35MRC Centre for Neuropsychiatric Genetics & Genomics, Institute of Psychiatry, Psychology and Neuroscience, School of Medicine, Cardiff University, Cardiff CF24 4HQ, UK. 36Sheffield Diagnostic Genetics Service, Sheffield Children’s NHS Foundation Trust, Western Bank, Sheffield S10 2TH, UK. 37University of Sussex, Brighton BN1 9RH, UK. 38Sussex Partnership NHS Foundation Trust, Swanead, Arundel Road, Worthing BN13 3EP, UK. 39University College London (UCL), UCL Genetics Institute, Darwin Building, Gower Street, London WC1E 6BT, UK. 40Bristol Genetic Epidemiology Laboratories, School of Social and Community Medicine, University of Bristol, Oakfield House, Oakfield Grove, Clifton, Bristol BS8 2BN, UK. 41Computational Biology & Genomics, Biogen Idec, 14 Cambridge Center, Cambridge, Massachusetts 02142, USA. 42Institute of Cardiovascular and Medical Sciences, University of Glasgow, Wolfson Medical School Building, University Avenue, Glasgow G12 8QQ, UK. 43Department of Medical and Molecular Genetics, Division of Genetics and Molecular Medicine, King’s College London School of Medicine, Guy’s Hospital, London SE1 9RT, UK. 44BGI-Shenzhen, Shenzhen 518033, China. 45University College London (UCL) Department of Genetics, Evolution & Environment (GEE), Gower Street, London WC1E 6BT, UK. 46MRC Integrative Epidemiology Unit, School of Social and Community Medicine, University of Bristol, Oakfield House, Oakfield Grove, Clifton, Bristol BS8 2BN, UK. 47University of Queensland Diamantina Institute, Translational Research Institute, Brisbane, Queensland 4102, Australia. 48MRC Human Genetics Unit, MRC Institute of Genetics and Molecular Medicine, at the University of Edinburgh, West General Hospital, Edinburgh EH4 2UX, UK. 49The Genome Centre, John Vane Science Centre, Queen Mary University of London, London E1 6QQ, UK. 50Cardiovascular Genetics, BHF Laboratories, Rayne Building, Institute of Cardiovascular Sciences, University College London, London WC1E 6JJ, UK. 51UCLA David Geffen School of Medicine, Los Angeles, California 90095, USA. 52Lady Davis Institute, Jewish General Hospital, Montreal, Quebec H3T 1E2, Canada. 53Department of Human Genetics, McGill University, Montreal, Quebec H3A 1B1, Canada. 54Department of Oncology, McGill University, Montreal, Quebec H2W 1S6, Canada. 55HeLEX – Centre for Health, Law and Emerging Technologies, Nuffield Department of Population Health, University of Oxford, Old Road Campus, Oxford OX3 7LF, UK. 56Department of Biology, University of Copenhagen, Ole Maaløes Vej 5, DK-2200 Copenhagen, Denmark. 57University College London (UCL), Molecular Psychiatry Laboratory, Division of Psychiatry, Gower Street, London WC1E 6BT, UK. 58Adaptive Biotechnologies Corporation, Seattle, Washington 98102, USA. 59Human Genetics Research Centre, St George’s University of London, London SW17 0RE, UK. 60Analytic and Translational Genetics Unit, Massachusetts General Hospital, Boston, Massachusetts 02114, USA. 61Program in Medical and Population Genetics, Broad Institute of Harvard and MIT, Cambridge, Massachusetts 02142, USA. 62National Cancer Research Institute, Angel Building, 407 St John Street, London EC1V 4AD, UK. 63Genetic Alliance UK, 4D Leroy House, 436 Essex Road, London N1 3OP, UK. 64South Thames Regional Genetics Lab, St George’s University, Cranmer Terrace, London SW17 0RE, UK. 65Schools of Mathematics and Social and Community Medicine, University of Bristol, Oakfield House, Oakfield Grove, Clifton, Bristol BS8 2BN, UK. 66Behavioural and Brain Sciences Unit, UCL Institute of Child Health, London WC1N 1EH, UK. 67Department of Medicine, Jewish General Hospital, McGill University, Montreal, Quebec H3A 1B1, Canada. 68BGI-Europe, London EC2M 4YE, UK. 69National Institute for Health and Welfare (THL), Helsinki FI-00271, Finland. 70Institute of Cardiovascular Science, University College London, Gower Street, London WC1E 6BT, UK. 71Cardiovascular Centre of the University of Lisbon, Faculty of Medicine, University of Lisbon, Avenida Professor Egas Moniz, 1649-028 Lisbon, Portugal. 72Wellcome Trust Centre for Human Genetics, Roosevelt Drive, Oxford OX3 7BN, UK. 73Illumina Cambridge Ltd, Chesterford Research Park, Cambridge CB10 1XL, UK. 74National Institute for Health Research (NIHR) Biomedical Research Centre at Guy’s and St Thomas’ Foundation Trust, London SE1 9RT, UK. 75Department of Statistics, University of Oxford, 1 South Parks Road, Oxford OX1 3TG, UK. 76Department of Genetics, Harvard Medical School, Boston, Massachusetts 02115, USA. 77The Patrick Wild Centre, The University of Edinburgh, Edinburgh EH10 5HF, UK. 78Department of Medical Sciences, University of Torino, 10124 Torino, Italy. 79Institute of Health Informatics, Farr Institute of Health Informatics Research, University College London (UCL), 222 Euston Road, London NW1 2DA, UK. 80Usher Institute of Population Health Sciences and Informatics, University of Edinburgh, 9 Little France Road, Edinburgh EH16 4UX, UK. 81Department of Mathematics, Université de Québec À Montréal, Montréal, Québec H3C 3P8, Canada. 82Institute for Molecular Medicine Finland (FIMM), University of Helsinki, Helsinki FI-00014, Finland. 83Program in Medical and Population Genetics and Genetic Analysis Platform, The Broad Institute of MIT and Harvard, Cambridge, Massachusetts 02132, USA. 84Institute of Neuroscience, Henry Wellcome Building for Neuroimaging, Newcastle University, Framlington Place, Newcastle upon Tyne NE2 4HH, UK. 85University of Helsinki, Department of Psychiatry, Helsinki FI-00014, Finland. 86North West Thames Regional
Kim Overvad\textsuperscript{11,12}, Anne Tjønneland\textsuperscript{13,14}, Françoise Clavel-Chapelon\textsuperscript{14}, Rudolf Kaaks\textsuperscript{11,15}, Heiner Boeing\textsuperscript{116}, Antonia Trichopoulou\textsuperscript{117,118}, Pietro Ferrari\textsuperscript{119}, Domenico Palli\textsuperscript{120}, Vittorio Krogh\textsuperscript{121}, Salvatore Panico\textsuperscript{122}, Rosario Tumino\textsuperscript{123}, Giuseppe Matullo\textsuperscript{124,125}, Jolandae Boe\textsuperscript{126}, Yvonne van. der. Schouw\textsuperscript{127}, Elisabeta Weiderpass\textsuperscript{128,129,130,131}, J. Ramon Quirós\textsuperscript{132}, María-José Sánchez\textsuperscript{133,134}, Carmen Navarro\textsuperscript{135,136}, Conchi Moreno-Iribas\textsuperscript{133,134}, Larrazc Arriola\textsuperscript{137}, Olle Melander\textsuperscript{138}, Patrik Wennberg\textsuperscript{139}, Timothy J. Key\textsuperscript{140} & Elio Riboli\textsuperscript{141}.

\textsuperscript{11}Department of Public Health, Section for Epidemiology, Aarhus University, Aarhus, Denmark. \textsuperscript{12}Department of Cardiology, Aalborg University Hospital, Aalborg, Denmark. \textsuperscript{13}Diet, Genes and Environment, Danish Cancer Society Research Center, Copenhagen, Denmark. \textsuperscript{14}INSEER, Centre for Research in Epidemiology and Population Health (CESP). \textsuperscript{15}French Cancer Research Center (CNRS), U1018, Nutrition, Hormones, and Women’s Health Team, Institut Gustave Roussy, Villejuif, France. \textsuperscript{16}Division of Cancer Genetic Epidemiology, German Cancer Research Centre (DKFZ), Im Neuenheimer Feld 581, 69121 Heidelberg, Germany. \textsuperscript{17}Department of Epidemiology, German Institute of Human Nutrition (DIfE), Potsdam-Rehbrücke, Germany. \textsuperscript{18}WHO Collaborating Center for Nutrition and Health, Unit of Nutritional Epidemiology and Nutrition in Public Health, Department of Hygiene, Epidemiology and Medical Statistics, University of Athens Medical School, Athens, Greece. \textsuperscript{19}Hellenic Health Foundation, Athens, Greece. \textsuperscript{20}ARC, Lyon, France. \textsuperscript{21}Molecular and Nutritional Epidemiology Unit, Centro per lo Studio e la Prevenzione Oncologico-Scientifico Institute of Tuscany, Florence, Italy. \textsuperscript{22}Epidemiology and Prevention Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy. \textsuperscript{23}Dipartimento di Medicina Clinica e Chirurgia, Federico II University, Naples, Italy. \textsuperscript{24}Cancer Registry and Histopathology Unit, Civic- M.P. Arezzo Hospital, ASP Ragusa, Italy. \textsuperscript{25}Human Genetics Foundation, Turin, Italy. \textsuperscript{26}Department of Medical Sciences, University of Turin, Italy. \textsuperscript{27}Centre for Nutrition, Prevention and Health Services, National Institute for Public Health and the Environment (RIVM), Bilthoven, The Netherlands. \textsuperscript{28}Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, The Netherlands. \textsuperscript{29}Department of Community Medicine, Faculty of Health Sciences, University of Tromsø, The Arctic University of Norway, Tromsø, Norway. \textsuperscript{30}Department of Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden. \textsuperscript{31}Genetic Epidemiology Group, Folkhälsan Research Center, Helsinki, Finland. \textsuperscript{32}Public Health Directorate, Asturias, Spain. \textsuperscript{33}Public Health Institute of Navarra, Pamplona, Spain. \textsuperscript{34}Red de Investigación en Servicios de Salud en Enfermedades Crónicas, Madrid, Spain. \textsuperscript{35}Epidemiology Department, Murcia Health Authority, Murcia, Spain. \textsuperscript{36}Centre de Investigación Biomédica en red en Epidemiología y Salud Pública, Barcelona, Spain. \textsuperscript{37}Public Health Division of Gipuzkoa, Instituto Bio-Donostia, Basque Government, CIBERESP, Spain. \textsuperscript{38}CRR, Lund University, 20502 Malmö, Sweden. \textsuperscript{39}Department of Public Health and Clinical Medicine, Family Medicine, Umeå University, Umeå, Sweden. \textsuperscript{40}Cancer Epidemiology Unit, Nuffield Department of Population Health, University of Oxford, Oxford, UK. \textsuperscript{41}German Cancer Research Center (DKFZ), Division of Cancer Epidemiology, Heidelberg, Germany.